ArticleTanaffos2023
Relation of Cognitive Impairment with Number of Acute Exacerbations and Serum Level of VEGF among COPD Patients.
Article in Tanaffos, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Progress of Research on Cognitive Impairment in Patients With Chronic Obstructive Pulmonary Disease.Actas espanolas de psiquiatria · 2026Review
- Endothelial progenitor cells and chronic obstructive pulmonary disease: From basic research to clinical application.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a main cause of morbidity and mortality in the world. Its complications are numerous and one of their most common extra-pulmonary ones is cognitive impairment which is directly related to its mortality and morbidity. A decrease in cerebral perfusion in these patients had been seen in previous studies considering the role of VEGF on angiogenesis and its role in the pathogenesis of COPD. This study was done to evaluate the relation of cognitive impairment with serum VEGF and the number of COPD exacerbations. Materials and Methods: In the present study, 87 patients whom the pulmonologist confirmed their COPD disease based on spirometry testing were enrolled. The blood sample was received for serum VEGF level measurement and the Mini-Mental State Examination (MMSE) questionnaire was completed to assess the cognitive function. The number of exacerbations was also recorded. The blood sample was received from 87 other age and sex-matched persons without a history of pulmonary disease, CVA, or MI. Their VEGF level was also measured. The data was analyzed by SPSS version 20 software. Results: In the COPD group, 42 (48.28%) had no cognitive impairment, 39 (44.83%) had mild, and 6(6.89%) had moderate cognitive impairment. In this group, there was a significant relation between the score of the MMSE questionnaire and the number of COPD exacerbations during the past year. However, there was no significant relation between VEGF and cognitive impairment. Conclusion: According to the results of the present study, there was no significant relation between cognitive impairment and VEGF level. There was a significant relation between cognitive impairment and the number of COPD exacerbations. Also, there was a significant difference between the serum level of VEGF among COPD patients and the control group.
Indexed as
Identifiers
38638387PMC11022191W4394962507What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.